Member Info for Laura2022

Wad totally lies on all counts

Please actually read

The £25 was retail NOT the main £400k one!!

Clown

M1rob

Highly unusual large buys

For PYC comapred to anything listed on Uk market

Also comapred to alot of corruption (eg GDR CEO was on £350k a year !) PYC BOD on very low salaries and if they hit £1.3mln revenues this year (already done £500k in month 1) /they could well hit break even

Thanks Earl

Cannot buy again

£20mln?

A soothing word from a central banker can have a big impact when traders are tearing their hair out about the future path of interest rates. Markets are calmer on Wednesday after the Bank of Japan (BoJ) dampened fears that another rate rise in Tokyo is imminent. Deputy governor Shinichi Uchida said the BoJ will stick with “current levels of monetary easing for the time being”, which helped the Topix up 4 per cent and the more tech-heavy Nikkei up 3 per cent overnight, as the yen softened.

The market volatility seen since late last week has been driven by a combination of Japan’s tightening of monetary policy (it increased rates last week for the second time this year to take them to their highest level in 15 years) and increased nervousness about a hard landing for the US economy. On Wall Street, both the S&P 500 and tech-focused Nasdaq were up 1 per cent yesterday.

The good news spread to the FTSE 100, which was up 1 per cent by mid-morning. Housebuilders Vistry (VTY) and Persimmon (PSN) were among the top risers, boosted by Halifax housing market data out today which showed that UK house prices rose 0.8 per cent in July. The Bank of England’s rate cut last week is helping housing market sentiment.

European bourses such as the Dax and Cac are also in the green, although a notably weak performer is Danish weight-loss drugmaker Novo Nordisk (DK:NOVO.B). Its shares are down 3 per cent after it reported worse-than-expected sales and profits

Apparently PYC have r tweeted Sheff U tweet so would expect news shortly

This was from a poster called Debull this morning

this is the post, its actually a repost or retweet in old money, so not technically a tweet as i first said.

https://x.com/sheffielduni/status/1820399409898586226

"A new form of immunotherapy could give new hope for prostate cancer.

@clancie55 research, funded by

@ProstateUKProfs, shows that using innovative nanoparticles can delay resistance to hormone therapy and help men with prostate cancer live longer."

I believe that Sheffield Uni got substantial funding from Yorkshire cancer research, hence why they have quite a few irons in the cancer fights fire. Be it the above or the fruit fly angle which PYC have collab'd on.

Sheep hatch

Also PYC have an A.I dosing app that can save millions and also a fully revenue generation product called "Virtual Tumour" - We think the major client mentioned in the june RNS could be AstraZeneca

And those like GPL UKOG etc etc weren't even generating revenues and had suffered mass dilution over 5yrs

PYC only has 200mln shares ...they have 5bln++

Ifnot already done so look at 10.03am summary very good from a long term hodler

The big one will be the NHS/DoseMeRx dosing tool which PYC have developed over the last 4yrs

That opens up Substantial revenues in USA and Europe via DoseMeRx clients (DoseMeRx ar also NASDAQ listed)

Late buys today and yesterday

Breaking out

This should be well higher than this and August saw many contracts last year

Sienna

We've explained before many times PYC has helped them with their main asset which is going to trials this H2

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK

GB

Our major long term client have huge cash resources and some are listed on NASDAQ too

Eg Bicycle who are $1.1 billio + cap with $500mln cash

https://www.google.com/finance/quote/BCYC:NASDAQ?sa=X&ved=2ahUKEwiE3Z2D0uKHAxU-UUEAHTD6E4kQ3ecFegQIHBAc

Yes GB

Some people here who know more than me

Worth clicking on posts by

Kinghomer

Trench123

See the 10.03am post

Hello GB

It's crazy valuation at £1.3mln marker cap .....for a company that achieved £900k last year and already booked £500k in first month of new calander year (July to June)

Other A.I software tech has been bought recently for $51mln for aprocate compa y generating not much more than PYC